NCT05258877View on ClinicalTrials.gov

Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 30, 2023

Conditions
Tuberculosis, Pulmonary
Interventions
OTHER

Plasma samples

Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.

Trial Locations (1)

7500

TASK Applied Sciences, Cape Town

Sponsors

Lead Sponsor

BioVersys AG
All Listed Sponsors
collaborator

TASK Applied Science

OTHER

lead

BioVersys AG

INDUSTRY

NCT05258877 - Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis. | Biotech Hunter | Biotech Hunter